Ulrik Pedersen-Bjergaard is a Clinical Professor of Endocrinology at the Department of Clinical Medicine. Dr. Pedersen-Bjergaard is affiliated with the Department of Endocrinology and Nephrology, Nordsjællands University Hospital Hillerød as a Chief Physician. He graduated from the University of Copenhagen as a medical doctor (MD) in 1986 and earned his Doctor of Medical Sciences in 2009. He is a board-certified specialist in General Internal Medicine and Medical Endocrinology.

Clinical work

In his clinical work, Dr. Pedersen-Bjergaard primarily takes care of patients with type 1 diabetes with a special expertise in glucose management and use of diabetes technology, but he also sees patients with type 2 diabetes, other endocrine diseases, and acute medical conditions.

Dr. Pedersen-Bjergaard’s research is primarily focused on glucose control in diabetes and the impact on outcomes of diabetes including acute diabetic complications, glycaemic, patient-reported, and long-term outcomes. His areas of interest include hypoglycaemia, insulin therapy, and diabetes technology including continuous glucose monitoring (CGM), automated insulin delivery (AID), and app’s supporting diabetes self-management.

• Dr. Pedersen-Bjergaard serves in advisory boards for Novo Nordisk and Sanofi
• Dr. Pedersen-Bjergaard has received speaker fees from Abbott, Novo Nordisk, and Sanofi
• Dr. Pedersen-Bjergaard has received research support from Novo Nordisk
• Dr. Pedersen-Bjergaard is a principal investigator in clinical trials sponsored by AstraZeneca, Bayer, and Novo Nordisk

Board memberships, research funds

Dr. Pedersen-Bjergaard serves as member of board in Fru Olga Bryde Nielsens Fond, Tvergaard Fonden, and Kaptajnløjtnant Harald Jensen og hustru’s Fond.

Major sources of research funding

The HypoADAPT study was supported by the Novo Nordisk Foundation with the grant number NNF17OC0028358. The HypoDeg trial was supported by an unrestricted grant from Novo Nordisk. The Hypo-RESOLVE research program was funded by the European Union’s Horizon 2020 program [the Hypo-RESOLVE-EU consortium], and the MELISSA study is funded by the European Union’s Horizon Europe program [the MELISSA-EU consortium]. Support has also been received from the Research Foundation of Nordsjællands Hospital.

Travel grants

Dr. Pedersen-Bjergaard has received travel support from Novo Nordisk and Sanofi.

As a clinical professor, I hold a dual appointment, meaning that I am employed both by the Capital Region of Denmark and the University of Copenhagen. For an overview of potential conflicts of interest, please refer to my research profile in the region.